GENESIS-PHARMA
12.1.2024 12:37:29 CET | Business Wire | Press release
GENESIS Pharma, a leading regional biopharma company operating in Europe, and Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, announce an exclusive distribution agreement for RIPRETINIB in 14 European markets in Central and Eastern Europe. Under the terms of the agreement, GENESIS Pharma will exclusively commercialize RIPRETINIB for the treatment of fourth-line gastrointestinal stromal tumor (GIST) in: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia.
RIPRETINIB is approved in the European Union for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Ms. Margarida Duarte, Senior Vice President, Head of International, Deciphera Pharmaceuticals stated: “We are excited to partner with GENESIS Pharma to distribute RIPRETINIB across Central and Eastern Europe, ensuring fourth-line GIST patients in these countries have access to this standard-of-care treatment. Deciphera is committed to commercializing RIPRETINIB globally, and our agreement with GENESIS Pharma builds upon the significant progress we have already made launching the therapy in Europe, positioning us well for continued growth as we work together to improve the lives of GIST patients”.
Mr. Constantinos Evripides, Managing Director of GENESIS Pharma stated: “We are pleased to expand the network of our international partners and honored that Deciphera recognized our expertise and track record in the commercialization of innovative biopharmaceutical products targeting severe and rare diseases. This agreement is an important step forward in expanding our geographical reach and delivering our mission to ensure that such products are made available to patients in the countries we operate. We look forward to joining forces with Deciphera to enable access to this important innovative therapy for eligible patients in Central and Eastern Europe”.
About Gastrointestinal stromal tumor (GIST)
Gastrointestinal stromal tumor (GIST) is a rare neoplasm of the gastrointestinal tract affecting the digestive tract or nearby structures within the abdomen, most often presenting in the stomach or small intestine1. GIST is the most frequent sarcoma of the gastrointestinal tract, with a reported incidence of 10-15 cases per million per year2. The majority of GISTs are driven by two oncogenic protein kinases, KIT and PDGFRA gain-of-function mutations. The most common primary mutations are in KIT kinase, representing approximately 80% of cases, or in PDGFRA kinase, representing approximately 5-10% of cases3. Current therapies are unable to inhibit the full spectrum of primary and secondary mutations, which drives resistance to most tyrosine kinase inhibitors (TKIs) therefore leading to disease progression4. Estimates for 5-year survival rate range from 48% to 90%, depending on the stage of the disease at diagnosis5.
About Deciphera
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, RIPRETINIB is Deciphera’s switch-control inhibitor for the treatment of fourth-line GIST. RIPRETINIB is approved in Australia, Canada, China, the European Union, Hong Kong, Iceland, Israel, Liechtenstein, Macau, New Zealand, Singapore, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and X (@Deciphera).
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharmagroup.com.
1. Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019 Feb;10(1):144-154.
2. Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016 Feb;40:39-46.
3. Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986498.
4. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7.
5. American Cancer Society. (March 1, 2023). Gastrointestinal stromal tumor survival rates. Retrieved December 21, 2023, from https://www.cancer.org/cancer/types/gastrointestinal-stromal-tumor/detection-diagnosis-staging/survival-rates.html.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240111379909/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICR Appoints Sukanti Ghosh as Partner, International Strategy & Markets18.2.2026 13:00:00 CET | Press release
Global Strategic Communications leader to drive ICR's expansion across Europe, Middle East, South Asia, and Africa ICR, a leading strategic communications and advisory firm, today announced the appointment of Sukanti Ghosh as Partner, International Strategy & Markets, effective February 2, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218511412/en/ Sukanti Ghosh headshot Based in London, Mr. Ghosh brings more than three decades of experience in global corporate affairs, financial communications, strategy, and issues management to ICR as the firm continues to grow its international footprint in Europe and across the Middle East, South Asia, and Africa. Mr. Ghosh joins ICR from the Vedanta Group, a $20bn diversified mining, energy and technology conglomerates, where he served as President of Global Policy & Communications and led financial communications for the group, globally. During his tenure, he also played a ce
Macrobond Recognized in G2’s 2026 Best Software Awards for Financial Services and New Software18.2.2026 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, today announced it has been named to G2’s 2026 Best Software Awards, earning recognition in the Best Financial Services Software Products and Best New Software Products categories. As the world’s largest and most trusted software marketplace, G2 reaches more than 100 million buyers annually. Its annual Best Software Awards rank the world’s leading software companies and products based on authentic, timely reviews from real users. “As buyers increasingly shift to AI driven research to discover software solutions, being recommended in the answer moment must be earned with credible proof,” said Godard Abel, co founder and CEO at G2. “Our Best Software Awards are grounded in trusted data from authentic customer reviews. They not only give buyers an objective, reliable guide to the products that help teams do their best work, but they are also the proof AI search platforms rely on when sourcing answers. Congratulations to
Tigo Energy Global Quality Program Marks 1,500 Green Glove Installer Engagements18.2.2026 12:00:00 CET | Press release
Continuous quality improvement produces better outcomes for solar customers with Green Glove installer support, and business process updates internally and in the field. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company’s vast network of solar installers has logged 1,500 Green Glove service program engagements. The Green Glove program helps reinforce the Company’s ongoing commitment to Total Quality Solar and deliver the best possible installer experience for participants, such as Brighthouse Solar of Central California. In addition to the Green Glove program, Tigo has deployed more than 12,000 customized onboarding sequences, across ten countries, to bring new installation companies up to speed on all things Tigo. From region-specific information to product and software training tips, these sequences are designed to ensure that installers have what they need based on their com
Battery Ventures Raises $3.25 Billion to Back Innovative Tech Companies Worldwide18.2.2026 10:00:00 CET | Press release
Battery—continuing to invest across the venture capital and buyout markets—has a single close on an oversubscribed fund Battery Ventures, the global, technology-focused investment firm, has closed a new, $3.25 billion fund to continue backing technology companies globally with a focus on the U.S., Europe and Israel. The new fund, Battery Ventures XV, comes on the heels of 15 announced exit events for the firm in 2025. Over the last five years Battery funds have realized more than $10 billion in liquidity, a testament to the firm’s stage-diversified approach. “We’re excited to build on our past success and partner with new, innovative companies in this dynamic market—driven, in large part, by the rise of artificial intelligence,” said Michael Brown, a Battery general partner. “To us, AI is ushering in one of the most consequential eras in the history of technology. We understand the gravity of this moment and feel well-suited to capitalize on the opportunity, given our global reach and
NICT Showcases Beyond 5G/6G Technologies at MWC Barcelona 202618.2.2026 09:00:00 CET | Press release
Japan's only national ICT research institute to present live demonstrations of terahertz-band wireless transmission, AI-driven communications, and advanced security technologies at Hall 6, Stand F54 National Institute of Information and Communications Technology (NICT), Japan’s leading public research organization in information and communications technology, today announced that it will exhibit at Mobile World Congress (MWC) Barcelona 2026, taking place from March 2–5, 2026, at Hall 6, Stand F54. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216620427/en/ NICT BOOTH NICT’s presence highlights Japan’s leadership in Beyond 5G and 6G research and development activities, addressing the growing limitations of current mobile networks as data traffic and connected devices continue to increase across Europe and globally. While 5G deployment is expanding, emerging applications such as AI-driven services, real-time analytics, and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom